LIVE UPDATES: Fed Chair Jerome Powell to deliver major speech at Jackson Hole
Monday, Mizuho (NYSE:MFG) Securities adjusted its outlook on BrightSpring Health (NASDAQ:BTSG) shares, raising the price target to $26.00 from the previous $22.00 while reiterating an Outperform rating. The revision follows BrightSpring Health’s strong performance in the first quarter of 2025 and an updated guidance that exceeded expectations. The company’s stock, currently trading at $20.87, has demonstrated remarkable momentum with a 20.57% return in the past week. InvestingPro data reveals analyst targets ranging from $20 to $31, suggesting potential upside.
The company’s recent financial results indicated a robust start to the year, prompting Mizuho to update its adjusted EBITDA forecasts for the years 2025 through 2027. With an EBITDA of $601.67 million and revenue of $11.86 billion in the last twelve months, BrightSpring Health has demonstrated strong operational performance. The firm’s analysts attribute this positive momentum to BrightSpring Health’s effective management and strategic positioning within the healthcare market, particularly in specialty drugs and the oncology generic pipeline. InvestingPro analysis shows the company maintains a GREAT financial health score of 3.14, reflecting its solid market position.
In a statement, the Mizuho analyst expressed confidence in the company’s trajectory, suggesting that the potential for growth outweighs any significant risks. The firm’s stance is backed by BrightSpring Health’s leverage in key growth areas, which are expected to continue driving the company’s financial performance.
The upgraded price target reflects a heightened optimism around BrightSpring Health’s future earnings and market position. Mizuho’s analysis concludes that the company is well-placed to capitalize on industry trends and continue its upward trajectory.
Investors have taken note of the new price target and Outperform rating, which underscore Mizuho’s belief in BrightSpring Health’s continued success and its ability to outperform the market. The company’s stock is poised to respond to these developments as the market processes the implications of Mizuho’s updated analysis.
In other recent news, BrightSpring Health Services reported a significant 26% increase in year-over-year revenue for Q1 2025, reaching $2.9 billion. Despite this impressive growth, the company’s earnings per share (EPS) of $0.19 fell slightly short of the forecasted $0.20. Pharmacy Solutions was a key contributor to this growth, with a 28% increase in revenue, totaling $2.5 billion. The company also announced plans to divest its Community Living business in the second half of 2025. Additionally, BrightSpring has been involved in discussions regarding potential acquisitions related to Amedisys (NASDAQ:AMED) assets, although details remain confidential. Analysts from Leerink Partners and Mizuho have shown interest in the company’s strategic initiatives and potential impacts of the Inflation Reduction Act (IRA) on future operations. BrightSpring continues to focus on expanding its primary care business and exploring value-based care models, as highlighted by CEO John Russo.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.